Antibodies News and Research

RSS

Potent nanobody binds SARS-CoV-2 spike in an extraordinary manner

In a new study, published recently on the bioRxiv preprint server, researchers isolated a nanobody that potently neutralizes SARS-CoV-2, including the B.1.351 variant, and cross-neutralizes SARS-CoV. They demonstrated the therapeutic potential of the nanobody in a human ACE2 (angiotensin-converting enzyme) transgenic mouse model.

24 Mar 2021

CureVac's COVID-19 vaccine protects mice against emerging SARS-CoV-2 variants

The CVnCoV mRNA vaccine showed neutralizing antibody levels and completely protected mice infected with the B.1.351 variant. No viral genomes were seen in oral swabs, lungs, or brain.

23 Mar 2021

Pilot study finds Bartonella infection in the blood of people with schizophrenia

A pilot study from North Carolina State University and the University of North Carolina at Chapel Hill has found evidence of Bartonella infection in the blood of people with schizophrenia and schizoaffective disorder.

23 Mar 2021

Study shows single dose of mRNA vaccine may suffice for those with prior SARS-CoV-2 infection

A recent study by researchers from Philadelphia, currently available on the medRxiv preprint server, shows that individuals with prior infection caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) exhibit substantial immune memory and develop a robust response to the first dose of an mRNA vaccine.

23 Mar 2021

Computational analysis reveals why new SARS-CoV-2 variants bind better to human cells

All viruses mutate as they make copies of themselves to spread and thrive. SARS-CoV-2, the virus the causes COVID-19, is proving to be no different. There are currently more than 4,000 variants of COVID-19, which has already killed more than 2.7 million people worldwide during the pandemic.

23 Mar 2021

Is T-cell receptor sequencing a reliable alternative to SARS-CoV-2 antibody testing?

Researchers in the United States have now demonstrated that T-cell receptor (TCR) sequencing might provide a reliable alternative to assessing infection in convalescent blood plasma, and may be applicable in the future for applying protective immunity to individuals.

23 Mar 2021

Correlation of antibody titers with COVID-19 vaccine efficacy

In a new study the relationship between virus-neutralizing antibody and spike protein-binding IgG antibody levels is explored following vaccination by one of seven currently deployed vaccines. The findings support the use of antibody titers as correlates of protection for COVID-19 vaccines.

23 Mar 2021

Immunoassay heterogeneity and implications for SARS-CoV-2 serosurveillance

In a recent study, scientists have quantified anti-SARS-CoV-2 antibody levels up to 9 months after infection.

23 Mar 2021

A new COVID-19 candidate vaccine induces robust humoral and cellular immune responses in mice

A Korea-based company EyeGene Inc. has recently developed a liposome-based mRNA candidate vaccine against COVID-19, which contains full-length spike protein of the European variant (D614G) of SARS-CoV-2 as a vaccine antigen.

23 Mar 2021

COVID-19 antibodies can protect against reinfection for at least eight months

A new study offers hope that recovered patients from COVID-19 are largely immune to reinfection for at least eight months.

23 Mar 2021

Study suggests SARS-CoV-2 antibodies in breast milk are robust, neutralizing and durable

A new study addresses the issue of passive immunity to SARS-CoV-2 for newborns via breast milk.

23 Mar 2021

Dandelion extract inhibits SARS-CoV-2 in vitro

An exciting new study describes a specific inhibitor of the SARS-CoV-2 found in an extract of the common dandelion that could provide a new and fruitful avenue of drug research.

23 Mar 2021

IONTAS identifies novel SARS-CoV-2 neutralising antibodies

IONTAS Limited (IONTAS) and FairJourney Biologics S.A (FJB)., leaders in the discovery and optimization of fully human antibodies, have announced the identification of neutralizing antibodies, which bind to multiple emerging SARS-CoV-2 variants.

From FairJourney Biologics 23 Mar 2021

Single BNT162b2 mRNA dose induces humoral and T cell responses against mutated variants with a history of COVID-19

In a paper recently uploaded to the preprint server bioRxiv by Tauzin et al. (March 18th, 2021) the ability of a single dose of mRNA vaccine to induce humoral and T cell responses against mutated variants are demonstrated and found to be reinforced in individuals with a history of COVID-19.

22 Mar 2021

Simple SARS-CoV-2 mutations allow escape from the majority of polyclonal antibodies

The group identified a single class of antibodies that target a particular epitope on the RBD of SARS-CoV-2, suggesting that the human polyclonal response to SARS-CoV-2 infection is dominated by a worryingly narrow range of antibodies that target an epitope undergoing rapid mutation.

22 Mar 2021

Most cancer patients with COVID-19 produce antibodies at a rate comparable to general population

Most people with cancer who are infected by the novel coronavirus produce antibodies at a rate comparable to the rest of the population--but their ability to do so depends on their type of cancer and the treatments they've received, according to a new study by researchers at Montefiore Health System and Albert Einstein College of Medicine.

22 Mar 2021

New method could drive down the production cost of antibodies

Antibody injections are a highly desirable treatment for people with chronic diseases such as cancer, psoriasis, Crohn's disease and arthritis. And recently, antibodies have been in the news as a promising treatment for severe cases of COVID-19.

22 Mar 2021

YAP inhibitors could facilitate targeted treatment of basal-like breast cancer

Targeted treatment of basal-like breast cancer could be facilitated by YAP inhibitors in the future. As reported by an MDC team headed by Walter Birchmeier in the scientific journal Cancer Research, this type of cancer requires the support of the YAP protein to stimulate the growth of cancer stem cells.

22 Mar 2021

AstraZeneca's COVID-19 vaccine protects against symptomatic disease

Results from a large clinical trial in the United States and South America indicate that AstraZeneca's COVID-19 vaccine, AZD1222, is well-tolerated and protects against symptomatic COVID-19 disease, including severe disease or hospitalization.

22 Mar 2021

Researchers develop new method for measuring immunity to coronavirus

Igor Stagljar made his career building molecular tools to combat cancer. But when the pandemic hit last March, he aimed his expertise at a new adversary, SARS-CoV-2.

22 Mar 2021

Antibodies News and Research

Potent nanobody binds SARS-CoV-2 spike in an extraordinary manner

CureVac's COVID-19 vaccine protects mice against emerging SARS-CoV-2 variants

Pilot study finds Bartonella infection in the blood of people with schizophrenia

Study shows single dose of mRNA vaccine may suffice for those with prior SARS-CoV-2 infection

Computational analysis reveals why new SARS-CoV-2 variants bind better to human cells

Is T-cell receptor sequencing a reliable alternative to SARS-CoV-2 antibody testing?

Correlation of antibody titers with COVID-19 vaccine efficacy

Immunoassay heterogeneity and implications for SARS-CoV-2 serosurveillance

A new COVID-19 candidate vaccine induces robust humoral and cellular immune responses in mice

COVID-19 antibodies can protect against reinfection for at least eight months

Study suggests SARS-CoV-2 antibodies in breast milk are robust, neutralizing and durable

Dandelion extract inhibits SARS-CoV-2 in vitro

IONTAS identifies novel SARS-CoV-2 neutralising antibodies

Single BNT162b2 mRNA dose induces humoral and T cell responses against mutated variants with a history of COVID-19

Simple SARS-CoV-2 mutations allow escape from the majority of polyclonal antibodies

Most cancer patients with COVID-19 produce antibodies at a rate comparable to general population

New method could drive down the production cost of antibodies

YAP inhibitors could facilitate targeted treatment of basal-like breast cancer

AstraZeneca's COVID-19 vaccine protects against symptomatic disease

Researchers develop new method for measuring immunity to coronavirus

Antibodies eBook

Pioneering Live Cell Imaging - Yokogawa's Impact and Innovations

Revolutionizing Life Science: An Interview with SCIEX on ASMS, the SCIEX 7500+ System, and AI-Driven Quantitation

From Discovery Biology to ELRIG Chair

Latest Life Science News